Sunday, August 19, 2018
Company News: Page (1) of 1 - 01/19/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018

(January 19, 2018)

Company announcement - No. 4/2018

Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018


  • Zealand receives FDA approval of its Investigational New Drug (IND) application for its Phase 3 program with dasiglucagon for treatment of congenital hyperinsulinism (CHI)  
  • Two Phase 3 trials are set to start within the coming months at leading centers in the U.S. and Europe
  • Zealand expects fast development progress to ultimately offer an effective non-surgical treatment for this rare disease affecting neonates and children
  • U.S. FDA and the European Commission have already granted orphan drug designation for dasiglucagon for the treatment of CHI in 2017

Copenhagen, Denmark, January 19, 2018 - The U.S. Food and Drug Administration (FDA) has approved Zealand's Investigational New Drug (IND) application for initiation of two Phase 3 clinical trials of dasiglucagon in CHI. This positive regulatory milestone and the current clinical evidence enable Zealand to proceed directly into Phase 3 development of dasiglucagon for the treatment of CHI.

CHI is a rare medical condition in neonates and children. Due to a genetic defect in the insulin producing cells, these children are born with too high blood insulin levels, resulting in persistent low blood glucose throughout childhood. Current treatment options are insufficient and the most severely affected children have the pancreas surgically removed within the first months of life in order control the blood glucose levels.  

In the Phase 3 program, Zealand will evaluate the potential of chronic dasiglucagon infusions delivered via a pump to prevent hypoglycemia in up to 50 children with CHI and thereby reduce morbidities associated with persistent hypoglycemia as well as neurodevelopmental defects and need for pancreatectomy

Dasiglucagon is a potential first-in-class glucagon analog invented and developed by Zealand. It is stable in aqueous formulation and suitable for pump use and thereby for potential treatment of (CHI). In 2017, the U.S. FDA and the European Commission both granted orphan drug designation for dasiglucagon for the treatment of CHI.

Britt Meelby Jensen, President and CEO of Zealand, comments:
"Congenital hyperinsulinism is a rare and severe disease, which affects newborns and children. I am very pleased with FDA's decision to approve our Phase 3 trials, as it allows us to make fast progression towards a potential treatment that can help these children and possibly save them from surgery with severe lifelong implications"

Dasiglucagon is in development for use in other indications
Dasiglucagon is in development for two additional indications:

  • Rescue treatment of severe hypoglycemia: Two Phase 3 trials ongoing in patients with type 1 diabetes for treatment in a ready-to-use rescue pen, with results expected in 2018.
  • Treatment of Type 1 Diabetes in a dual-hormone artificial pancreas pump containing both insulin and glucagon (dasiglucagon), with potential to bring a paradigm shift in treatment. Positive results reported from two Phase 2a studies in 2017, and a Phase 2b proof-of-concept trial is planned for 2018.

For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: [email protected]

Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a late stage pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit or follow Zealand on LinkedIn or Twitter @ZealandPharma.


Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines